Podcasts about Esophageal cancer

Listen as we discuss the highly-awaited ESOPEC trial, which examines treatment regimens for esophageal and EGJ adenocarcinoma. Wildly impress your thoracic attendings or peers with your nuanced knowledge! FLOT who? You'll know. Pull out the paper and listen along! Learning Objectives: -Discuss the patient population in the ESOPEC trial -Discuss the main differences between the ESOPEC trial and the CROSS trial -Describe the main drawbacks between FLOT and the CROSS regimen. Hosts: Chloe Hanson MD, Brian Louie MD, and Peter White MD   Referenced Material https://www.nejm.org/doi/full/10.1056/NEJMoa2409408 Hoeppner J, Brunner T, Schmoor C, Bronsert P, Kulemann B, Claus R, Utzolino S, Izbicki JR, Gockel I, Gerdes B, Ghadimi M, Reichert B, Lock JF, Bruns C, Reitsamer E, Schmeding M, Benedix F, Keck T, Folprecht G, Thuss-Patience P, Neumann UP, Pascher A, Imhof D, Daum S, Strieder T, Krautz C, Zimmermann S, Werner J, Mahlberg R, Illerhaus G, Grimminger P, Lordick F. Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer. N Engl J Med. 2025 Jan 23;392(4):323-335. doi: 10.1056/NEJMoa2409408. PMID: 39842010. https://www.nejm.org/doi/full/10.1056/NEJMoa1112088 van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A; CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012 May 31;366(22):2074-84. doi: 10.1056/NEJMoa1112088. PMID: 22646630. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32557-1/abstract Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag GM, Luley K, Lindig U, Schmiegel W, Pohl M, Stoehlmacher J, Folprecht G, Probst S, Prasnikar N, Fischbach W, Mahlberg R, Trojan J, Koenigsmann M, Martens UM, Thuss-Patience P, Egger M, Block A, Heinemann V, Illerhaus G, Moehler M, Schenk M, Kullmann F, Behringer DM, Heike M, Pink D, Teschendorf C, Löhr C, Bernhard H, Schuch G, Rethwisch V, von Weikersthal LF, Hartmann JT, Kneba M, Daum S, Schulmann K, Weniger J, Belle S, Gaiser T, Oduncu FS, Güntner M, Hozaeel W, Reichart A, Jäger E, Kraus T, Mönig S, Bechstein WO, Schuler M, Schmalenberg H, Hofheinz RD; FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019 May 11;393(10184):1948-1957. doi: 10.1016/S0140-6736(18)32557-1. Epub 2019 Apr 11. PMID: 30982686. ***Fellowship Application Link: https://forms.gle/PQgAvGjHrYUqAqTJ9 Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more. If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

Continuing with Esophageal Cancer awareness month, Dr. Parikh interviews Dr. Lishan Aklog, who is chairman and CEO of Lucid Diagnostics. They discuss esophageal cancer pathophysiology, prevalence and the current state of esophageal cancer screening.  They then shift their focus to EsoGuard, a novel screening tool for Barrett's esophagus and esophageal cancer.This episode is brought to you by Lucid Diagnostics maker of the EsoGuard test for early detection of esophageal precancer.

April is Esophageal Cancer awareness month. Dr. Parikh interviews fellow gastroenterologist, Dr. George Sun. They discuss the epidemiology, risk factors, and symptoms of esophageal cancer before briefly providing an overview of treatment modalities. This episode is brought to you by Castle Biosciences, maker of TissueCypher, a test designed to predict the risk of esophageal cancer in patients with Barrett's esophagus.

Join Michael and Ashlee (AKA mom) as they talk to Mark Sevillano and his mom, Yolanda. Mark went through an aggressive esophageal cancer that left him unable to swallow. Unable to eat. A single dad, he was so fortunate to have his family, in particular his incredible mom, beside him as he went through chemo, surgery, and more (or less!) chemo. Mark discovered that he needed to listen to his own body. Make his own decisions. And learn to destress his very stressful life. Mark and his mom are so full of hope and optmism! You will feel their good energy and so much love and connection. A common theme of both Michael and mom ashlee. https://www.instagram.com/mrmarktheofficiant/

In this episode of the Becker's Healthcare Podcast, host Lukas Voss explores cutting-edge advancements in gastric and esophageal cancer care with two leading experts from City of Hope. Surgical Oncologist Dr. Yanghee Woo and Medical Oncologist Dr. Dani Castillo discuss the benefits of a multidisciplinary approach, the impact of robotic-assisted minimally invasive surgery, and the latest clinical trials offering new hope for patients.This episode is sponsored by City of Hope.

CT scan accidentally reveals calcium deposits where they don't belong; Dispelling the myth that hunter-gatherers get more sleep than Westerners; Blue light exposure at night impairs sleep—but morning exposure improves it; When normal B12 levels aren't enough; NT Factor vs. urolithin A (Mitopure®️) for mitochondria; Alternatives to PPIs for Barrett's Esophagus; Topical—not oral—melatonin for skin rejuvenation. 

Cancer of the esophagus is a tough cancer to treat, and more people worldwide are developing it. A recent study compares one regimen giving chemotherapy and radiation before surgery versus another strategy using four chemotherapy drugs plus surgery. William Nelson, … What is the best way to treat esophageal cancer? Elizabeth Tracey reports Read More »

Endoscopic submucosal dissection in the esophagus: Michal Kaminski from Warsaw reviews prior, current and future indications

Send us a textAre you one of the many who experience heartburn or acid reflux? In our latest episode, host Debra Schindler separates fact from fiction about gastroesophageal reflux disease -or GERD- with MedStar Health gastroenterologist Vinshi Khan, MD. Learn why long term complications from GERD make treatment so important. If you have feedback on this podcast, or would like to make an appointment with Dr. Kahn, send us an email, at debra.schindler@medstar.net.For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.

“Active holistic therapy” for prostate cancer with diet and fish oil helps defer need for surgery, hormone blockade, radiation; Why 70 is the new 60; Long-term harmful effects of acid-blockers; Do memory supplements pass the blood-brain barrier? Fish oil, krill oil, olive oil for cardiovascular prevention; Paxlovid aggressively promoted but overprescribed for otherwise healthy patients. 

Dr Christopher Lieu shares his perspectives on the evolving therapeutic landscape for patients with colorectal and gastroesophageal cancers, moderated by Dr Stephen "Fred" Divers. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/AON24).

To have your question featured in a future video, please email: questions@drmdc.health

When he was diagnosed with stage 4 esophageal cancer at the age of 64, Shane Gallup of New York state underwent conventional treatment. He thought he had beaten it but the cancer returned two years later. Undeterred, Shane opted for cannabis oil and today he is cancer free and here to share his journey, his challenges, and how cannabis played a pivotal role in his recovery. Visit our website: CannabisHealthRadio.comFollow us on Facebook.Follow us on Instagram.Find us on Rumble.Keep your privacy! Buy NixT420 Odor Remover

In this podcast, we discuss the The Society of Thoracic Surgeons/American Society for Radiation Oncology Updated Clinical Practice Guidelines on Multimodality Therapy for Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction. Joining in the discussion are Dr. Stephanie Worrell, Associate Professor and Thoracic Section Chief in the Division of Cardiothoracic Surgery at the University of Arizona College of Medicine, and Dr. Karyn Goodman, Professor and Vice Chair for Research and Quality at the Icahn School of Medicine at Mount Sinai, and Associate Director for Clinical Research at The Tisch Cancer Institute, who served as chair and co-chair of the guideline panel, respectively. Together, we cover important updates and recommendations that incorporate surgical aspects into the multi-disciplinary management of this disease along with practical considerations for everyday practice. Additionally, we discuss in depth the recently presented ESOPEC trial presented at the 2024 ASCO annual meeting and how it has impacted the standard of care for esophageal cancers.

In this podcast, we discuss the The Society of Thoracic Surgeons/American Society for Radiation Oncology Updated Clinical Practice Guidelines on Multimodality Therapy for Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction. Joining in the discussion are Dr. Stephanie Worrell, Associate Professor and Thoracic Section Chief in the Division of Cardiothoracic Surgery at the University of Arizona College of Medicine, and Dr. Karyn Goodman, Professor and Vice Chair for Research and Quality at the Icahn School of Medicine at Mount Sinai, and Associate Director for Clinical Research at The Tisch Cancer Institute, who served as chair and co-chair of the guideline panel, respectively. Together, we cover important updates and recommendations that incorporate surgical aspects into the multi-disciplinary management of this disease along with practical considerations for everyday practice. Additionally, we discuss in depth the recently presented ESOPEC trial presented at the 2024 ASCO annual meeting and how it has impacted the standard of care for esophageal cancers.

In this podcast, we discuss the The Society of Thoracic Surgeons/American Society for Radiation Oncology Updated Clinical Practice Guidelines on Multimodality Therapy for Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction. Joining in the discussion are Dr. Stephanie Worrell, Associate Professor and Thoracic Section Chief in the Division of Cardiothoracic Surgery at the University of Arizona College of Medicine, and Dr. Karyn Goodman, Professor and Vice Chair for Research and Quality at the Icahn School of Medicine at Mount Sinai, and Associate Director for Clinical Research at The Tisch Cancer Institute, who served as chair and co-chair of the guideline panel, respectively. Together, we cover important updates and recommendations that incorporate surgical aspects into the multi-disciplinary management of this disease along with practical considerations for everyday practice. Additionally, we discuss in depth the recently presented ESOPEC trial presented at the 2024 ASCO annual meeting and how it has impacted the standard of care for esophageal cancers.

In this podcast, we discuss the The Society of Thoracic Surgeons/American Society for Radiation Oncology Updated Clinical Practice Guidelines on Multimodality Therapy for Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction. Joining in the discussion are Dr. Stephanie Worrell, Associate Professor and Thoracic Section Chief in the Division of Cardiothoracic Surgery at the University of Arizona College of Medicine, and Dr. Karyn Goodman, Professor and Vice Chair for Research and Quality at the Icahn School of Medicine at Mount Sinai, and Associate Director for Clinical Research at The Tisch Cancer Institute, who served as chair and co-chair of the guideline panel, respectively. Together, we cover important updates and recommendations that incorporate surgical aspects into the multi-disciplinary management of this disease along with practical considerations for everyday practice. Additionally, we discuss in depth the recently presented ESOPEC trial presented at the 2024 ASCO annual meeting and how it has impacted the standard of care for esophageal cancers.

In early 2020, it became difficult for Clinton to eat. It was during the pandemicand much harder at the time to see a doctor, so it took a while before he was able to get checked out. In January 2021, Clinton was diagnosed with esophageal cancer that metastasized into his lungs. His treatment included six months on a feeding tube, chemotherapy and radiationtreatments. In summer 2021, he received an esophagectomy and now comes in forchemotherapy every other week. He will continue these sessions for the foreseeablefuture. The American Cancer Society estimates that there will be about 22,370 newesophageal cancer cases diagnosed (17,690 in men and 4,680 in women) in 2024. Esophageal cancer is more common among men than among women. Thelifetime risk of esophageal cancer in the United States is about 1 in 127 in men andabout 1 in 434 in women.

In this episode of Empowering Plans, The Phia Group's CLO – Ron Peck – sits down with experienced surgeon, Dr. Victoria Lee, to discuss a very dangerous – and costly – threat.  Esophageal cancer is generally considered to be a death sentence, and historically screening options are invasive and costly, resulting in a low uptake.  With the introduction of EsoGuard, however, plans can identify which participants are at risk, and have them tested quickly, non-invasively, and inexpensively.  You can save lives and money… but you cannot afford to miss this episode.  For those interested in learning more about EsoGuard, please contact Jim Fricchione, Vice President – Employer Markets with Lucid Diagnostics, at 617-921-7949 or JMF@LucidDX.com.

Healing your gut is the key to living longer…but what does that really mean? Is your reflux from too much acid or too little? Is your autoimmune challenge connected to your stomach? It is! Tune in to learn how to nurture your gut, avoid dis-ease, and reduce inflammation in this episode with Dr. Daryl Gioffre, the founder of Kick Acid Enterprises.This week, Jenn is joined by the founder of Kick Acid Enterprises, Dr. Daryl Gioffre. After witnessing his father die from esophageal cancer, Dr. Gioffre made the promise that he would prevent others from suffering the same way his father had. Dr. Gioffre discusses the connection between acid, gut health, inflammation, and sugar and why managing these things is crucial for living healthy. He explains the three critical problems in everybody's health while providing steps to overcome these issues in a balanced way. Tune in to learn more about acidity in our bodies and the key role it plays. The Salad With a Side of Fries podcast is hosted by Jenn Trepeck, discussing wellness and weight loss for real life, clearing up the myths, misinformation, bad science & marketing surrounding our nutrition knowledge and the food industry. Let's dive into wellness and weight loss for real life, including drinking, eating out, and skipping the grocery store.IN THIS EPISODE: [6:22] Dr. Daryl Gioffre tells us his story and what changed the course of his life and led him to become a gut specialist.[11:15] What is the connection between acid, gut health, inflammation and sugar? [15:12] What is the cause of dis-ease and why are doctors getting it wrong? [17:30] What are the three critical problems for everybody's health? [20:33] What are some signs of low stomach acid?[23:56] How can you support healthy acid?[27:05] What foods can help support proper gut health and function? [31:58] Can you drink coffee while managing your acid health? [34:26] How does alcohol affect the acidity in our body?[37:37] How do sweeteners affect our acid? [40:15] What do we need to know about sugar and how it relates to gut health and inflammation? KEY TAKEAWAYS: The best way to help increase the acid in your stomach is to take 1 tbsp apple cider vinegar + ⅓ cup warm water, and drink it 20-30 minutes prior to your biggest meal of the day. Those with acid reflux should start with ½ tsp + ⅓ cup warm water. This must be done with consistency. Artificial sweeteners are the very worst thing you can put into your body, you need to avoid them like the plague if you want to be healthy. Healing your gut is the key to healthy skin, to lowering your weight, to better brain function. That is the key to living longer. QUOTES: [11:18] “No one dies of old age, you know there's all these different diseases out there like heart disease and cancer. By the way, cancer has now overtaken heart disease as a number one killer in 21 states. You've got to understand our genes have not changed for 40,000 years, so it's not a gene issue. This is an epigenetic issue, which means the lifestyle choices we make, how you think, how you eat, how you move, lack thereof, that is going to dictate your longevity, your quality of life, and the quality of your energy.” - Dr. Daryl Gioffre [12:12] “For the first time in human history, our children have less of a lifespan than we do.” - Dr. Daryl Gioffre[15:26] “When I say get off your acid, I'm not referring to the acid in your stomach. I'm referring to the acidity in your tissues that's causing you to rust and rot from the inside out.” - Dr. Daryl Gioffre"The acid in your stomach is your first line of defense." - Dr. Daryl Gioffre"This is about fitting things into your life, not the other way around." - Dr. Daryl Gioffre"The average cup of coffee is 100x more acidic than tap water." - Dr. Daryl Gioffre[38:58] “Artificial sweeteners are dangerous, they're poison. Aspartame metabolizes into a couple of different amino acids, but one of those is actually methanol, which comes from wood alcohol, and that metabolizes into formaldehyde in your body. So literally when you are taking in these artificial sweeteners, you're putting the same things that they embalm dead bodies with into your body.” - Dr. Daryl GioffreRESOURCES:Become A Member of Salad with a Side of FriesJenn's Free Menu PlanA Salad With a Side of FriesA Salad With A Side Of Fries MerchA Salad With a Side of Fries InstagramGUEST RESOURCESGet Off Your Acid WebsiteGet Off Your Acid InstagramDr. Daryl Gioffre's InstagramGet Off Your Acid TwitterGet Off Your Acid FacebookGUEST BIODr. Gioffre is a highly sought-after gut health and inflammation specialist with over two decades of experience in the field.  Having overcome a life-long sugar addiction, in addition to his own gut and mold toxicity issues, he knows firsthand what it takes to overcome adversity and challenges in the pursuit of superior health.In addition to running the successful Alkamind brand, he is the founder of Kick Acid Enterprises, a virtual nutritional testing and coaching platform focusing on getting to the root cause of inflammation by restoring, balancing and strengthening the microbiome, what he calls GutFitness.He is also a board-certified chiropractor, Reiki Master, certified raw food chef, and author of the best-selling books Get Off Your Acid, and newly released Get Off Your Sugar: Burn the Fat, Crush Your Cravings, and Go From Stress Eating to Strength Eating.Dr. Gioffre has appeared on ‘Live with Kelly and Ryan', Good Morning America, Access Hollywood, The Doctors, Extra, E News, People Magazine, Vogue, Daily Mail, Page Six, and more to discuss his Acid-Kicking approach to health and fitness.He is a passionate motivational speaker and has been featured in many health documentaries and health summits, and currently sits on Fran Drescher's Cancer Schmancer Medical and Wellness Advisory Board.Dr. Gioffre lives in Naples, Florida with his wife Chelsea, and two children, Brayden and Alea, and dogs Sprout and Barley.

Comprehensive, relevant and insightful conversations about health and medicine from the largest healthcare system in the Maryland D.C. region: this is MedStar Health DocTalk.In our latest podcast episode, host Debra Schindler talks with thoracic surgeon Dr. Duane Monteith and gastroenterologist Dr. Dana Sloan for a comprehensive look into esophageal cancer. They discuss everything from early symptoms and risk factors to advanced treatment options like minimally invasive surgery. This episode is packed with valuable insights that could make a significant difference in early detection and treatment. For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.

Prof Eric Van Cutsem from University Hospitals Leuven in Leuven, Belgium, discusses recent updates on available and novel treatment strategies for gastroesophageal cancer, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/YiR2023/Gastroesophageal2).

Host: Darryl S. Chutka, M.D., [@chutkaMD] Guest: Tanios S. Bekaii-Saab, M.D. Although esophageal cancer is not a common malignancy, when found it often has a poor prognosis. It's about four times more likely to occur in a male than a female. Although a variety of malignancies can develop in the esophagus, most tend to be either squamous cell or adenocarcinoma. Fortunately, the rates of esophageal cancer have been decreasing slightly over the past decade. Despite the fact that esophageal cancer often produces symptoms, the survival rate has not been very good, although due to new and improved treatments it has been improving. The topic for today's podcast is esophageal cancer and my guest is Tanios S. Bekaii-Saab, M.D., the division chair for Hematology/Oncology at the Mayo Clinic in Phoenix, Arizona. We'll discuss the risk factors for esophageal cancer, its common presenting symptoms, how to establish a diagnosis and the various treatment options available. Connect with the Mayo Clinic's School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Dr. Kirsten Newhams, a board-certified surgeon with the AHN Esophageal Institute, joins Larry and Marty to discuss Esophageal Cancer Month. 

This April, Oncology Data Advisor is raising awareness for Esophageal Cancer Awareness Month. In this interview, Oncology Data Advisor Editorial Board and Fellows Forum members Dr. Joseph Kalis, Dr. Matthew Hadfield, and Dr. Samuel Kareff discuss rising trends, treatment advances, and emerging management strategies for esophageal cancer, including the following: • The rising rate of adenocarcinoma in the context of pre-existing esophageal dysplasia and Barrett esophagus • Risk factors such as tobacco and alcohol • The roles of healthy eating and smoking cessation in esophageal cancer prevention • How the rise of immunotherapies such as pembrolizumab, nivolumab, and trastuzumab have changed practice • This month's approval of fam-trastuzumab deruxtecan-nxki for human epidermal growth factor receptor 2 (HER2)–positive solid tumors • Lifestyle interventions such as following the Mediterranean diet and United States Preventive Services Task Force (USPSTF) exercise guidelines that can make maximize tolerability of therapy

Esophageal Cancer Awareness Month with guest Michael Hurwitz March 31, 2024

Dr Yelena Y Janjigian from Memorial Sloan Kettering Cancer Center in New York and Dr Zev Wainberg from UCLA Jonsson Comprehensive Cancer Center in Los Angeles discuss the management of gastroesophageal cancers and review emerging data sets in the field, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/YiR2023/Gastroesophageal).

Betel quid chewing, a traditional custom widely practiced in South Asia, Southeast Asia, the Asia-Pacific region, and East Africa for centuries, involves the consumption of raw areca nut mixed with slaked lime and wrapped in a betel leaf. This habit is particularly popular in certain regions, including Northeast India, where the areca nut is raw, wet, and consumed unprocessed. The act of chewing and swallowing this mixture leads to the release of alkaloids, polyphenols, and tannins. However, the consumption of raw areca nut betel quid has been strongly associated with the development of oral, esophageal, and gastric cancers, and has adverse consequences on oral health. Several studies have shown a significant relationship between periodontitis and betel quid chewing habits in many countries, including India. In this context, esophageal cancer is a devastating disease that affects millions of people around the world. Recent research has shed light on the role of the Mad2 gene in the development and progression of esophageal cancer, a disease strongly associated with the consumption of raw areca nut betel quid. In a new study, researchers Chongtham Sovachandra Singh, Nabamita Boruah, Atanu Banerjee, Sillarine Kurkalang, Pooja Swargiary, Hughbert Dakhar, and Anupam Chatterjee from The Assam Royal Global University, University of Pennsylvania, LN Mithila University, University of Chicago Medicine, Nazareth Hospital, Laitumkhrah, and North-Eastern Hill University provide valuable insights into the molecular mechanisms underlying Mad2 gene deregulation in esophageal cancer. On February 5, 2024, their new research paper was published in Oncotarget's Volume 15, entitled, “Differential expression of Mad2 gene is consequential to the patterns of histone H3 post-translational modifications in its promoter region in human esophageal cancer samples.” Full blog - https://www.oncotarget.org/2024/02/22/raw-areca-nut-betel-quid-consumption-and-esophageal-cancer/ Paper DOI - https://doi.org/10.18632/oncotarget.28554 Correspondence to - Anupam Chatterjee - achatterjee@rgu.ac, chatterjeeanupam@hotmail.com Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28554 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, Mad2 gene, histone methylation, histone acetylation, Rb-phosphorylation; esophageal cancer About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Case-based workup and management of esophageal cancer in radiation oncology.

BUFFALO, NY- February 12, 2024 – A new research paper was published in Oncotarget's Volume 15 on February 5, 2024, entitled, “Differential expression of Mad2 gene is consequential to the patterns of histone H3 post-translational modifications in its promoter region in human esophageal cancer samples.” Raw areca nut (AN) consumption increases esophageal squamous cell carcinoma (ESCC) due to overexpression of securin (pituitary tumor transforming gene1), causing chromosomal instability. Mitotic arrest deficient protein 2 (Mad2), a crucial spindle assembly checkpoint protein, is at risk of aneuploidy and tumor development when overexpressed or underexpressed. In this new study, researchers Chongtham Sovachandra Singh, Nabamita Boruah, Atanu Banerjee, Sillarine Kurkalang, Pooja Swargiary, Hughbert Dakhar, and Anupam Chatterjee from The Assam Royal Global University, University of Pennsylvania, LN Mithila University, University of Chicago Medicine, Nazareth Hospital, Laitumkhrah, and North-Eastern Hill University evaluated Mad2 status in human ESCC with AN consumption habits, revealing unclear molecular mechanisms. Human ESCC samples (n = 99) were used for loss of heterozygosity analysis at 4q25-28, while 32 samples were used for expression analysis of Mad2, E2F1 genes, and Rb-phosphorylation. Blood samples were used for metaphase preparation. The Mad2 deregulation was assessed using chromatin immunoprecipitation-qPCR assay in the core promoter region, establishing its association with the pRb-E2F1 circuit for the first time. “The study revealed overexpression and underexpression of Mad2, premature anaphase, and chromosome missegregation in all the samples.” LOH pattern identified a deletion in D4S2975 in 40% of ESCC samples. The study reveals the deregulation of pRb-E2F1 circuit in all samples. 4q27 disruption could be a factor for Mad2 underexpression in AN-induced esophageal carcinogenesis, while overexpression may be due to the deregulation of the Rb-E2F1 circuit and consequently elevation of H3K4me3 and H3K9ac. “Mad2 expression levels with chromosomal abnormalities can be a clinical biomarker, but further research is needed to understand pRb's role in Mad2 down-regulation.” DOI - https://doi.org/10.18632/oncotarget.28554 Correspondence to - Anupam Chatterjee - achatterjee@rgu.ac, chatterjeeanupam@hotmail.com Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28554 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, Mad2 gene, histone methylation, histone acetylation, Rb-phosphorylation; esophageal cancer About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Amitabh Chak, MD, Sanford Markowitz, MD, PhD, and Joseph Willis, MD, explain the journey of EsoCheck™ and EsoGuard™, an incredible bench to bedside diagnostic discovery to detect Barrett's esophagus and prevent esophageal cancer.

1/6/24 - Host Doug Stephan and Dr. Ken Kronhaus of Lake Cardiology (352-735-1400) cover a number of topics, Including: 7 healthy New Years Resolutions, Dr. Ken explains Lp(a) and why you need to have yours checked with your next blood work, 20% of adults have inherited Lp(a) genetically, salt's effects on your Kidneys, the best substitutes for salt, "Tummy Tucks" have been determined to be safe and reliable, giving up alcohol completely could help prevent Oral or Esophageal Cancer, there is a new pill for Postpartum Depression, why you should consider the latest COVID vaccination.

Create Sales meetings in minutes. Lisa Thal is an Author, Speaker, and Business Coach. She has over 36 years of marketing, sales, and leadership experience. She wrote the book "Three Word Meetings."  Lisa coaches leaders on creating sales and business meetings with fun and interesting 3-word topics to create a conversation and inspire your sales team.   Episode 223 is about Believing in Something!  Three words that we could use to achieve our dreams and goals.    The Holiday season reminds us of one word: Believe. Do you have kids, or if you are an adult, think back to when you were a kid waiting for Santa and Rudolph to visit. How did you feel? I remember feeling excitement and anticipation of Something good, a special moment. I believed.   If you are a Ted Lasso fan, as I am, one word appeared in the locker room: Believe.     Believe in Something!    These three words have become a staple in our house.   The past few months have been challenging for our family. My wife Olivia was unexpectedly diagnosed with Esophageal Cancer. We learned that when Liv had an endoscopy done for reflux, she was experiencing. This news was shocking to us. Liv eats all the right foods, exercises daily, enjoys Mountain Biking, volunteers to coach Kids, and loves to experience the great outdoors.      Her daily routines have shifted from riding trails to driving to radiation and chemo treatments each day for weeks, not to mention the mental challenges she faces daily from the effects of the treatments. How does she manage this each day? The food she can eat from the impact of the treatments. She believes in Something. She is fighting for her life. She can live another day to spend with her family, hiking the pups, seeing her friends, her biking community, and her siblings, nieces, and nephews! She Believes! We believe in a cure!   The question is, what is it that you Believe?   We are all entering a new year, the perfect time to reflect on the past and plan for the future. Many people are excited to say goodbye to last year's challenges and welcome the potential of the future. However, along with the new year comes the need for new goals.    While setting goals can feel overwhelming, believing in Something can be the motivator you need to help you achieve them. Believing in Something can be one of the most powerful tools for success. We'll dive into the power of believing in Something and how it can help make this year your best year yet.   The Power of Believing in Something   Believe in Yourself  The first step in believing in Something is to believe in yourself. You may have doubts or fears, but it is essential to push past them to achieve your goals. Believe in your abilities, skills, and strengths. Recognize your accomplishments, no matter how small they may seem, and use them as fuel to keep pushing your life. Believe that you can achieve anything with hard work and dedication.     Believe in Your Vision  Your vision drives you forward, and it's essential to believe in it. Don't be afraid to dream big and set lofty goals. Your vision should be Something you are passionate about and will motivate you to work hard. Whether it's a personal or professional goal, believing in your vision will help you stay focused and determined throughout the year.     Believe in Your Team  As important as it is to believe in yourself and your vision, it's equally important to believe in your team. Liv has a team of Doctors and nurses helping us Beat Cancer. You can only achieve some things, and having a solid support system can make all the difference. Whether it's your colleagues, family, or friends, trust in their abilities and work together to achieve your goals. Believe in each other and push each other to succeed.     Believe in Resilience  Believing in Something means that everything will go differently than it is. There may be setbacks and challenges, but resilience can help you overcome them. Have faith in your ability to bounce back, and don't let setbacks discourage you. Remember that failure is not the end but a learning opportunity, a new beginning. Keep pushing forward, and believe that you will succeed in the future.     Believe in Your Purpose The most significant belief that you can have is in your purpose. What is it that drives you? What energizes you? What motivates you to achieve your goals? Keep your intention at the forefront of everything you do and believe in its value. With a clear purpose, you will stay dedicated and focused throughout the year.     Believing in Something requires you, your determination, and a vision for the future. Now is the perfect time to reflect on your goals for the coming year and embrace the power of belief. Believe in yourself, your vision, your team, your resilience, and your purpose, and use these beliefs as fuel to drive you toward success. With this mindset, you can achieve anything, no matter how big or small the goal may be. Stay focused, work hard, and maintain your belief; this year can be your best. Believe you can, and you will!   And if someone can benefit from hearing this, please share it.   Create engaging sales meetings in minutes!  My easy-to-use process can quickly create impactful meetings tailored to your team's needs.    Learn more at www.Threewordmeetings.com.

Featuring a discussion on optimizing the management of gastroesophageal cancers with Dr Samuel J Klempner, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/MTPGastroesophageal23/Part3).

Dr. Lishan Aklog, CEO of Lucid Diagnostics, discusses the current diagnostic landscape for esophageal cancer and the need for early detection. The current diagnostic tool, an upper endoscopy, is an invasive procedure requiring anesthesia.  The EsoGuard, a noninvasive simple cell collection procedure, uses molecular diagnostics to detect pre-cancerous cells within minutes. This test is particularly beneficial for screening those with risk factors such as chronic heartburn, being male, a smoker, or obese.   Lishan explains, "To prevent it, you have to pick it up at the pre-cancer stage because, unlike many other cancers where detecting earlier stage cancer, stage one cancer is a victory with a real potential for a cure, such as in breast cancer and colon and others, that's not the case here. You have about a 50% likelihood of dying even if you pick up esophageal cancer at the earliest stages. So, our mission and the opportunity here is to prevent about 16,000 cancer deaths a year by detecting the pre-cancerous conditions before it actually becomes cancer." "Using modern molecular techniques, we can identify the pre-cancerous cells at their earliest stage, which is groundbreaking. There is no other cancer that can be detected in the early pre-cancer stage at the 80% levels that we're able to do with this new test called EsoGuard. It's been on the market for a few years. So, that completely changes the landscape. Now, we have the opportunity to offer a very simple, noninvasive test that can detect the pre-cancerous condition in 80% of people. It also detects the cancer in 100% of people who happen to be unfortunate enough to have that. It is great opportunity, great shift in the landscape thanks to great science." #LucidDiagnostics #EsoGuard #UpperEndoscopy #EsophagealCancer #PreCancer luciddx.com Listen to the podcast here

Dr. Lishan Aklog, CEO of Lucid Diagnostics, discusses the current diagnostic landscape for esophageal cancer and the need for early detection. The current diagnostic tool, an upper endoscopy, is an invasive procedure requiring anesthesia.  The EsoGuard, a noninvasive simple cell collection procedure, uses molecular diagnostics to detect pre-cancerous cells within minutes. This test is particularly beneficial for screening those with risk factors such as chronic heartburn, being male, a smoker, or obese.   Lishan explains, "To prevent it, you have to pick it up at the pre-cancer stage because, unlike many other cancers where detecting earlier stage cancer, stage one cancer is a victory with a real potential for a cure, such as in breast cancer and colon and others, that's not the case here. You have about a 50% likelihood of dying even if you pick up esophageal cancer at the earliest stages. So, our mission and the opportunity here is to prevent about 16,000 cancer deaths a year by detecting the pre-cancerous conditions before it actually becomes cancer." "Using modern molecular techniques, we can identify the pre-cancerous cells at their earliest stage, which is groundbreaking. There is no other cancer that can be detected in the early pre-cancer stage at the 80% levels that we're able to do with this new test called EsoGuard. It's been on the market for a few years. So, that completely changes the landscape. Now, we have the opportunity to offer a very simple, noninvasive test that can detect the pre-cancerous condition in 80% of people. It also detects the cancer in 100% of people who happen to be unfortunate enough to have that. It is great opportunity, great shift in the landscape thanks to great science." #LucidDiagnostics #EsoGuard #UpperEndoscopy #EsophagealCancer #PreCancer luciddx.com Download the transcript here

Prof Eric Van Cutsem from the University Hospitals Leuven in Leuven, Belgium, discusses optimizing the management of gastroesophageal cancers, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/MTPGastroesophageal23/Part2).

On Tuesday's Morning Focus, Alan was joined by Michael Daffy member of the fundraising committee and Ken Butler, survivor of Esophageal Cancer to discuss Cycle4Des. The aim of Cycle4Des is to raise money to help fight oesophageal cancer. Clare FM previously heard from Fergal Lynch, Co-organiser of the cycling fundraiser, that his own father Des passed away due to esophageal cancer. The cycle, will leave Quin, with the finish line in Athenry and is set to take place this Saturday.

Featuring a discussion on current and emerging strategies for the treatment of upper GI cancers with Dr Peter C Enzinger, moderated by Dr Neil Love. CME information and select publications here (https://www.researchtopractice.com/MTPGastroesophageal23/Part1)

Dr Philip Philip from Henry Ford Cancer - Detroit in Michigan discusses key presentations on GI cancers from the 2023 ASCO Annual Meeting moderated by Dr Neil Love. Produced by Research to Practice. CME information and select publications here (https://researchtopractice.com/OncologyTodayPostASCO23/GI)

Dr Tanios Bekaii-Saab from the Mayo Clinic in Phoenix, Arizona, discusses the role of novel therapeutic management approaches for patients with colorectal and gastroesophageal cancers. NCPD information and select publications here (https://www.researchtopractice.com/ONS2023GE/AudioInterview)

This week's episode will be focusing on Esophageal and Gastrosophageal Junction (GEJ) Cancers. We will go over high yield details on the risk factors, diagnosis, and treatment for both localized and metastatic esophageal cancer.

When he was diagnosed with esophageal cancer, surgery was performed along with chemo and radiation, but later he was told that his cancer had spread to his lymph nodes, liver and lung. That's when he was given the grim news that he only had about 11 months to live. Feeling that continuing chemotherapy would kill him, Dave Gallant and his wife Marilyn, from British Columbia, Canada, started on cannabis oil. A recent scan found "no evidence of disease."

This case covers the anatomy, histology, pathology, and clinical features of GERD, Barrett's esophagus, and esophageal cancer. The corresponding video is on YouTube (https://youtu.be/UrC_UT8k0qM).   **Thank you to our sponsor Doc2Doc Lending, the Personal Lending platform designed for Doctors, by Doctors. Check out https://doc2doclending.com/davinci to learn more today.   DaVinci Academy YouTube Channel: https://www.youtube.com/@DaVinciAcademyMed Website: https://www.dviacademy.com/

Bob and Lisa host a support group of Esophageal Cancer survivors over for a five-day hangout. The group met on a Zoom chat about a year ago and have gotten close. Bob saw no need to check anyone's pockets on departure. Ever seen any Cirque du Soleil shows? Bob raves about 'Michael Jackson One' and how was a feast for the senses with the incredible surround sound and no-net acrobatics. Which leads to discussing Michael's controversies and how the Vegas show made subtle reference through symbolism. Did MJ kinda get a pass? After talking about the 'KISW 90's reunion' that Joe attended & enjoyed seeing all the old faces.. The guys reminisce about Seattle's grunge heyday in the early 90's and talk about the current state of Seattle; homelessness, drug overdoses, graffiti, garbage and crime. Joe teases he has something in common with Hollywood movie stars, which is the use of the diabetic drug, Ozempic, for weight loss. Hollywood discovered this and started using it off-label, leading to people paying thousands of dollars for it. Joe's unsure of its effectiveness on him due to a high tolerance to drugs - and cuz.. eating - a lifelong habit that's hard to break. BSJ get some tips how to be better podcasters/hosts from an unlikely source.. the importance of accepting compliments graciously and expressing gratitude towards others. They touch on the difficulty of balancing listening and speaking when hosting a show and how this can sometimes cause hosts to come off as insensitive to compliments. We re-spin a great clip o'yesteryear when Lewis Black ( @OfficialLewisBlack / https://www.lewisblack.com ) visited the studio. Black discusses his comedic style, which he describes as being an optimist who is let down by reality every day… his philosophy on socialism, his formal education in drama and Broadway plays.. one he wrote that never made to stage. Joe visits family in Tucson. Southwest living is calling. Listening to the audio on Podcast Service? See the Video at: - BobRivers.com - https://bobrivers.com/thebobriversshow_20230417 or- YouTube - https://www.youtube.com/watch?v=5MLKpjmkAMk --> ( Please 'Like' and 'Subscribe'

Paul joins Teresa again to discuss his surgery and treatments of his cancer journey. If...

Healthy Liver, Hogwarts Legacy, Continental Breakfast, Nephilim, Dwarfism Benefits, Birthdays, Kosher Foods, Cross Guards, Esophageal Cancer, and much much more!

We are so excited to put out the 100th episode and what a treat! Teresa's...

Barrett's esophagus is a condition in which the lining esophagus becomes damaged by acid reflux, which causes the lining to thicken and become red. Over time, the valve between the esophagus and the stomach may begin to fail, leading to acid and chemical damage of the esophagus, a condition called gastroesophageal reflux disease, or GERD.  In some people, GERD may trigger a change in the cells that line the lower esophagus, causing Barrett's esophagus."The stomach is well designed to handle highly acidic conditions," explains Dr. James East, a gastroenterologist at Mayo Clinic Healthcare in London. "But the esophagus is not designed to cope with acid. And so when acid comes up, that acid reflux damages the cells, replacing them with more acid-resistant cells that develop into Barrett's esophagus." While frequent heartburn may be a sign, many people with Barrett's esophagus have no symptoms. Having Barrett's esophagus does increase your risk of developing esophageal cancer. Although the cancer risk is small, it's important for people with Barrett's esophagus to have regular checkups to check for precancerous cells. Those at highest risk for Barrett's esophagus include:  White men over the age of 50. People with family history of Barrett's esophagus or esophageal cancer. People who smoke.  People with excess abdominal fat.  Patients with long-standing reflux lasting more than five years.  "If you have three of those risk factors, then you should have a screening endoscopy for Barrett's esophagus, according to current guidelines," says Dr. East. To screen for Barrett's esophagus, a lighted tube with a camera at the end, called an endoscope, is passed down the throat to check for signs of changing esophagus tissue. A biopsy is often done to remove tissue and confirm the diagnosis.Treatment for Barrett's esophagus depends on the extent of abnormal cell growth in your esophagus and your overall health. Treatments in the early stages can include lifestyle measures and medications to help reduce acid reflux and therefore, the esophageal acid exposure. If the cell damage is more extensive, radiofrequency ablation may be be used. In this technique, a balloon is used to heat the abnormal esophagus tissue and burn it away. Another technique, cryotherapy, applies cold liquid or gas to destroy the abnormal cells.The best way to prevent Barrett's esophagus is to address acid reflux and GERD through lifestyle changes."Lifestyle measures that reduce the risk of reflux are the key here because once Barrett's esophagus develops, it's a permanent change unless we use some of the ablation techniques," says Dr. East. "So absolutely quit smoking, and limit alcohol and caffeine. And even losing a small amount of weight can really help reduce reflux symptoms."On the Mayo Clinic Q&A podcast, Dr. East discusses diagnosing and treating Barrett's esophagus.